These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1314 related items for PubMed ID: 32964766

  • 1. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S.
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [Abstract] [Full Text] [Related]

  • 2. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [Abstract] [Full Text] [Related]

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 4. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U, Weber B, Sarr C, Freiwald M.
    BMC Pulm Med; 2021 Jul 21; 21(1):244. PubMed ID: 34289823
    [Abstract] [Full Text] [Related]

  • 5. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U, Weber B, Magnusson MO, Freiwald M.
    Respir Med; 2021 Jul 21; 180():106369. PubMed ID: 33798871
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M, Azuma A.
    Mod Rheumatol; 2020 Mar 21; 30(2):225-231. PubMed ID: 31747840
    [Abstract] [Full Text] [Related]

  • 9. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P, Drakopanagiotakis F, Wygrecka M.
    Dtsch Med Wochenschr; 2021 Feb 21; 146(3):181-184. PubMed ID: 33513653
    [Abstract] [Full Text] [Related]

  • 10. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD, Kugler MC, Deshwal H, Munger JS, Condos R.
    Lung; 2020 Aug 21; 198(4):597-608. PubMed ID: 32591895
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
    Inoue Y, Kitamura H, Okamoto M, Ogura T, Nishioka Y, Kuwana M, Taniguchi A, Ito T, Rohr KB, Suda T.
    Respir Investig; 2024 Jul 21; 62(4):589-596. PubMed ID: 38692040
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T.
    Respir Med; 2021 Oct 21; 187():106574. PubMed ID: 34564020
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR, INBUILD Trial Investigators.
    Arthritis Rheumatol; 2022 Jun 21; 74(6):1039-1047. PubMed ID: 35199968
    [Abstract] [Full Text] [Related]

  • 19. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M, Tschoepe I, Coeck C, Lievens D, Costabel U.
    Respir Res; 2022 Apr 07; 23(1):85. PubMed ID: 35392908
    [Abstract] [Full Text] [Related]

  • 20. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR, INBUILD trial investigators.
    Eur Respir J; 2022 Feb 07; 59(2):. PubMed ID: 34210788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.